Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Classical psychedelics, primarily psilocybin and lysergic acid diethylamide (LSD), have been used and extensively studied in Western medicine as part of substance-assisted psychotherapy in the 1950s and 1960s. Modern clinical research is currently gaining momentum and provides new evidence for the safety and efficacy of classical psychedelics (primarily psilocybin, but also LSD and ayahuasca) in the treatment of different psychiatric conditions, including substance use and mood disorders. In this review article, we outline common pathological mechanisms of substance use disorders (SUD) and unipolar depression. Next, the current literature on the effects of psychedelics is summarized in order to generate hypotheses regarding their potential therapeutic mechanisms of action in treating these psychiatric conditions. Finally, we review and discuss clinical trials published since 2011 investigating the effects of psychedelics in SUD and depression. While results from those modern clinical trials are promising, most of them do not meet the methodological requirements to allow firm conclusions on the clinical efficacy of psychedelics. Larger, blinded, randomized controlled trials (RCT) with clearly defined patient groups and well-defined primary endpoints are needed. Additionally, the therapeutic mechanisms of classical psychedelics are currently unknown. This review presents hypotheses derived from preclinical and human studies that need to be tested in future trials to better understand the clinical potential of psychedelic substances in modern psychiatry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Kaiser, R. H., Andrews-Hanna, J. R., Wager, T. D., & Pizzagalli, D. A. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0071 · Cited by 2,281
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009 · cited 1×
“Research consistently points towards a causal role of HPA-axis dysfunction in the etiology of depression, where altered glucocorticoid receptors might lead to HPA-axis hyperactivity, hypercortisolemia, neuronal atrophy, and impaired neurogenesis down the line [21, 22].”
BackgroundAntidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Chronic stress, drug use, and vulnerability to addiction
Sinha, R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.030 · Cited by 1,904
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“Preclinical and clinical research suggests synaptic loss in cortical and limbic areas, decreased neurogenesis, cortical (especially in the prefrontal cortex) and subcortical (hippocampus and other limbic structures) atrophy as well as depletion of brain derived neurotrophic factor (BDNF) are associated with depression…”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Epigenetic regulation in psychiatric disorders
Tsankova, N., Renthal, W., Kumar, A., & Nestler, E. J. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2132 · Cited by 1,400 · cited 1×
“The glucocorticoid receptors mediate the effects of cortisol to stress; accordingly, changes in their expression may lead to long-lasting and altered reactivity of the HPA-axis and hence stress reactivity and sensitivity [56, 57]—a risk factor in the development of stress-induced psychopathologies like depression.”
BackgroundSynaptic plasticity and addiction
Kauer, J. A., & Malenka, R. C. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2234 · Cited by 1,397 · cited 1×
“It has been proposed that drugs of abuse hijack synaptic plasticity mechanisms and thus enable the formation of persistent links between reinforcing aspects of the experience and associated cues [34].”
BackgroundThe stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Caspi, A., Hariri, A. R., Holmes, A., Uher, R., & Moffitt, T. E. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101452 · Cited by 1,346
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“, [152], as has recently also been recommended by the FDA and National Institutes of Health (NIH) (www.”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“, [154, 155]) to few (at least 1, often more) preparation and integration sessions between the patients and their respective monitors/therapists present during the dosing session (e.”
BackgroundStetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123 · cited 1×
“Research consistently points towards a causal role of HPA-axis dysfunction in the etiology of depression, where altered glucocorticoid receptors might lead to HPA-axis hyperactivity, hypercortisolemia, neuronal atrophy, and impaired neurogenesis down the line [21, 22].”
BackgroundKreek, M. J., Nielsen, D. A., Butelman, E. R., & LaForge, K. S. (2005) · Nature Neuroscience · doi:10.1038/nn1583 · Cited by 1,024 · cited 1×
“Often these gene variants are also involved in impulsivity, risk-taking, or stress-responsivity—traits that have been shown to influence the development and persistence of addiction [58].”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“, [2, 90, 91]—psychedelics also interact with other receptor types, including other serotonergic receptors (e.”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Liu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
The addicted human brain: insights from imaging studies
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18533 · Cited by 916 · cited 2×
“SUD The Reward System Drugs of abuse have a strong reinforcing effect that is associated with increases in dopamine concentration in the striatum [81].”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“, [154, 155]) to few (at least 1, often more) preparation and integration sessions between the patients and their respective monitors/therapists present during the dosing session (e.”
BackgroundGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Dwivedi, Y., Rizavi, H. S., Conley, R. R., Roberts, R. C., Tamminga, C. A., & Pandey, G. N. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.8.804 · Cited by 875
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Interaction between BDNF and Serotonin: Role in Mood Disorders
Martinowich, K., & Lu, B. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301571 · Cited by 793 · cited 1×
“Notably, an interaction between 5-HT and BDNF levels has been reported, with BDNF promoting survival and differentiation of 5-HT neurons, and antidepressant medication enhancing BDNF gene expression [29].”
BackgroundSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 3×
“The scientific investigation of these substances was catalyzed by the discovery of the psychological effects of LSD in 1943 by Albert Hofmann [1].”
BackgroundMethodInfluentialMolendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 1×
“A recent meta-analysis provides evidence for decreased BDNF serum levels in depressed patients [25].”
BackgroundLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Social functioning in major depressive disorder
Kupferberg, A., Bicks, L., & Hasler, G. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.07.002 · Cited by 663 · cited 2×
“, a lack of interest in social relationships and social affiliation), increased sensitivity to social rejection, and impaired social communication due to impaired emotion recognition and negative emotional biases outlined above, to deficits in social perception and understanding of others (including empathy and theory…”
BackgroundHow do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 2×
“In qualitative interviews, depressed patients emphasized the subjective experience of connectedness to oneself, the world, and others and an increased willingness to accept emotions as a key component of the acute psilocybin experience [147].”
BackgroundLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Self-citationCognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Reward Processing in Depression: A Conceptual and Meta-Analytic Review Across fMRI and EEG Studies
Keren, H., O’Callaghan, G., Vidal-Ribas, P., Buzzell, G. A., Brotman, M. A., Leibenluft, E., Pan, P. M., Meffert, L., Kaiser, A., Wolke, S., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101124 · Cited by 521 · cited 1×
“While the general notion seems to be a blunted response within the reward circuit, particularly the ventral striatum, a recent meta-analysis provides evidence for opposing abnormalities in the reward circuit, including hypo-responses in the ventral striatum and hyper-responses in the orbitofrontal cortex [73, 74].”
BackgroundGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520 · cited 1×
“Healthy participants reported increases in interpersonal closeness and positive/ altruistic social effects up to 14 months after the administration of psilocybin and LSD [118, 119].”
BackgroundMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 1×
“, [2, 90, 91]—psychedelics also interact with other receptor types, including other serotonergic receptors (e.”
BackgroundThe role of 5-HT receptors in depression
Yohn, C. N., Gergues, M. M., & Samuels, B. A. (2017) · Molecular Brain · doi:10.1186/s13041-017-0306-y · Cited by 485
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390 · cited 8×
“All rights reserved. is reduced in associative brain regions including the DMN [143, 145].”
BackgroundInfluentialSelf-citationEmotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375 · cited 1×
“, 1 week after psilocybin administration [135].”
Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
Self-citationVollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305 · cited 1×
“Evidence is mostly derived from preclinical studies, but one human positron emission tomography (PET) trial also revealed increased striatal dopamine levels following a psilocybin dose [93].”
BackgroundPsychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis
Ma, Y. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.24 · Cited by 270
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267 · cited 1×
“In vivo and in vitro studies have shown that psychedelics produce a potent anti-inflammatory effect (for a detailed review, see [113]).”
BackgroundEffects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 2×
“The authors also found dose-dependent decreases in hippocampal neurogenesis, although for the low psilocybin dose, a trend toward increased neurogenesis was evident [112].”
BackgroundGoldstein, R. Z., Alia-Klein, N., Tomasi, D., Zhang, L., Cottone, L. A., Maloney, T., Telang, F., Caparelli, E. C., Chang, L., Ernst, T., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.43 · Cited by 258
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247 · cited 1×
“Additionally, both LSD and psilocybin acutely increase emotional empathy [121, 122].”
BackgroundNg, T. H., Alloy, L. B., & Smith, D. V. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0644-x · Cited by 244
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235 · cited 1×
“Accordingly, as also suggested by a recent metaanalysis [46], anti-inflammatory agents could be an effective treatment strategy in MD and SUD.”
BackgroundLong-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230 · cited 1×
“However, it has also been reported that depressed patients show increased amygdala reactivity in response to fearful faces and decreased amygdala-prefrontal cortex functional connectivity the morning after treatment with psilocybin [136, 137].”
Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Walker, S. J., Mickey, B. J., Koeppe, R. A., Langenecker, S. A., & Zubieta, J.-K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.185 · Cited by 205 · cited 1×
“[80] revealed decreased responsivity of the social reward system during social acceptance as well as altered endogenous opioid activity in stress regulating brain regions during social rejection in depressed individuals compared to healthy controls.”
BackgroundEffect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197 · cited 1×
“Additionally, both LSD and psilocybin acutely increase emotional empathy [121, 122].”
BackgroundSelf-citationFoland-Ross, L. C., & Gotlib, I. H. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00489 · Cited by 197
Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183 · cited 1×
“The authors concluded that changes in 5-HT2A levels are likely variable across individuals, but that those changes might still be relevant for long-term psychological or clinical effects of psychedelics [100].”
BackgroundAltered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172 · cited 1×
“Emotional empathy also has been shown to be enhanced the morning after a psilocybin retreat, an effect that endured up to 7 days for negative emotions [123].”
BackgroundEffects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169 · cited 1×
“Psilocybin furthermore acutely reduced social rejection processing and the feeling of social exclusion [124].”
BackgroundSelf-citationNichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · cited 1×
“Rodent studies, however, consistently show a widespread upregulation of different genes and their translation into proteins, primarily those involved in synaptic plasticity, neural signaling, and memory, in various brain regions (including the cortex, amygdala, nucleus accumbens, and striatum) after LSD and DOI exposu…”
BackgroundPsychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · cited 1×
“Given that addiction and mood disorders have been associated with increases in inflammation markers as outlined above, it has been proposed that the anti-inflammatory properties of psychedelics may contribute to the long-lasting therapeutic effects after only a single dose [116].”
BackgroundNeurotrophins and Psychiatric Disorders
Castrén, E. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-45106-5_17 · Cited by 150
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141 · cited 1×
“Increased adrenocorticotropic hormone (ACTH) and cortisol levels have been found in humans after oral administration of different psychedelic substances, including LSD [108], psilocybin [109], and ayahuasca a DMT-containing plant brew [110].”
BackgroundHamilton, P. J., & Nestler, E. J. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.05.005 · Cited by 137
Epigenetics of drug abuse: predisposition or response
Nielsen, D. A., Utrankar, A., Reyes, J. A., Simons, D. D., & Kosten, T. R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.94 · Cited by 125 · cited 2×
“These drug-induced epigenetic changes may influence reward processing, drug craving, and relapse [65].”
BackgroundGodlewska, B. R., & Harmer, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-019-05448-0 · Cited by 123 · cited 2×
“The cognitive neuropsychological hypothesis of antidepressant action even proposes that antidepressant treatments decrease the negativity bias during emotional processing first, which leads to clinically significant mood improvement only later in the course of treatment after interactions with the social environment a…”
BackgroundZellner, M. R., Watt, D. F., Solms, M., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.01.003 · Cited by 112 · cited 1×
“This is particularly interesting with respect to recent models suggesting that SUD and depression may be linked through the same pathological emotionalaffective mechanisms arising from a dysregulation of dopaminergic and endogenous opiate signaling that usually support social attachment [89].”
BackgroundKraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.08.009 · Cited by 104 · cited 1×
“Psilocybin decreased the connectivity from the amygdala to the primary visual cortex during threat processing [132] and reduced the connectivity between the amygdala and the striatum during angry face discrimination [133].”
BackgroundSelf-citationFunctional changes of the reward system underlie blunted response to social gaze in cocaine users
Preller, K. H., Herdener, M., Schilbach, L., Stämpfli, P., Hulka, L. M., Vonmoos, M., Ingold, N., Vogeley, K., Tobler, P. N., Seifritz, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317090111 · Cited by 104
Self-citationModulating limbic-cortical circuits in depression: Targets of antidepressant treatments
Mayberg, H. S. (2002) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2002.35223 · Cited by 102
Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033693 · Cited by 102 · cited 1×
“Furthermore, methamphetamine has been shown to elevate the expression of TNF-α in mice [44] and to increase IL-6 and TNF-α levels in cultures of rat microglial cells [45].”
BackgroundReduced awareness of others’ emotions in unipolar depressed patients
Donges, U.-S., Kersting, A., Dannlowski, U., Lalee-Mentzel, J., Arolt, V., & Suslow, T. (2005) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000161683.02482.19 · Cited by 89
Modulation of Social Cognition via Hallucinogens and “Entactogens”
Preller, K. H., & Vollenweider, F. X. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00881 · Cited by 71
Self-citationShared neural basis of social and non-social reward deficits in chronic cocaine users
Tobler, P. N., Preller, K. H., Campbell-Meiklejohn, D. K., Kirschner, M., Kraehenmann, R., Stämpfli, P., Herdener, M., Seifritz, E., & Quednow, B. B. (2016) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsw030 · Cited by 50
Self-citation
Cited by
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101809 · Cited by 354
Self-citationLey, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01607-2 · Cited by 130
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“Precise mechanisms underlying the psychopathology reduction are complex and multifaceted, involving changes in neural networks, psychological processes, and self-reported altered resting states [95].”
BackgroundMertens, L. J., Koslowski, M., Betzler, F., Evens, R., Gilles, M., Jungaberle, A., Jungaberle, H., Majić, T., Ströhle, A., Wolff, M., et al. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100104 · Cited by 41
“For a thorough discussions on the modern clinical trials with psilocybin and other classical psychedelics, see the existing reviews by Mertens and Preller (2021) or Rucker et al. (2018).”
InfluentialSelf-citation
Metadata
- Authors
- Mertens, L. J., & Preller, K. H.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2021-01-20
- Volume
- 54
- Issue
- 04
- Pages
- 176-190
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W3124059976
- Cited by
- 65
- References
- 87
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.